Role

The OPTN works to maintain an equitable organ allocation system for patients on the national waitlist through: (1) data-driven organ allocation policy development and implementation; (2) quality improvement; and (3) technology, which is used to match donor organs to transplant candidates.

OPTN projects can include changes to allocation policy, bylaws, data collection, member requirements, guidance documents, white papers, and patient education materials. OPTN committees initiate projects.

The OPTN’s role is governed by the National Organ Transplant Act (NOTA) and the Final Rule.

The OPTN contract has been competitively bid 8 times since the OPTN’s establishment in 1986. The current OPTN contract has been extended by HRSA through March 29, 2024.

Role

HRSA awards the competitively bid contract to operate the OPTN, oversees the OPTN contractor, and approves the OPTN registration fee collected from transplant programs to add patients to the waitlist in accordance with the Final Rule. The registration fee comprises approximately 90% of the OPTN’s funding with the rest being appropriated by Congress.

HRSA also awards the competitively bid contract to operate the Scientific Registry of Transplant Recipients (SRTR) and oversees this contractor. SRTR conducts special studies and advanced statistical analyses of OPTN data in accordance with NOTA that inform the OPTN Board action.

In 2000, HRSA issued a Final Rule establishing the regulatory framework for the structure and operations of the OPTN. The Final Rule requires the Secretary of Health and Human Services (the Secretary) to approve proposed policies prior to implementation that the OPTN Board recommends be enforceable. It also grants the Secretary the authority to consult with the Advisory Committee on Organ Transplantation (ACOT) on proposed policies.

Role

OPOs

CMS issued a regulation in November 2020 revising outcome measure requirements and conditions for coverage for organ procurement organizations (OPOs). CMS set forth a process to decertify OPOs, at which point Medicaid and Medicare will not reimburse the decertified OPO for services.

Transplant Programs

A condition of participation in the Medicare program for transplant programs is membership in the OPTN.

Donor Hospitals

CMS’ conditions for participation require hospitals to report to OPOs patient-level data of individuals whose death is imminent or who have died in the hospital.

Histocompatibility Laboratories

CMS regulates all laboratory testing, including histocompatibility testing, performed on humans through the Clinical Laboratory Improvement Amendments (CLIA).
Leadership

The OPTN Final Rule\textsuperscript{xvi} outlines the composition of the OPTN Board and requires the board to be composed as follows:

- Approximately 50 percent transplant surgeons or transplant physicians;
- At least 25 percent transplant candidates, transplant recipients, organ donors and family members. These members should represent the diversity of the population of transplant candidates, transplant recipients, organ donors and family members served by the OPTN including, to the extent practicable, the minority and gender diversity of this population. These members shall not be employees of, or have a similar relationship with OPOs, transplant centers, voluntary health organizations, transplant coordinators, histocompatibility experts, or other non-physician transplant professionals; however, the OPTN Board may waive this requirement for not more than 50 percent of these members; and
- Representatives of OPOs, transplant hospitals, voluntary health associations, transplant coordinators, histocompatibility experts, non-physician transplant professionals, and the general public.

The OPTN Charter\textsuperscript{xvii} notes that the third category of Board members should include at least one member representing pediatric-specific interests. The Charter also outlines that the Contracting Officer’s Representative (COR) for the OPTN Contract and the Director of the Division of Transplantation, within the Health Resources and Services Administration, HHS, or their designees, will serve as ex-officio, non-voting members.\textsuperscript{xx}

The OPTN and the contractor have used a unitary board approach since the inception of the OPTN. HRSA has stated that OPTN board independence could strengthen public trust in oversight and accountability.\textsuperscript{xx}

Leadership

HRSA’s Division of Transplantation is responsible for managing and overseeing the OPTN and SRTR contractors.\textsuperscript{xix}

Leadership

CMS’s Center for Clinical Standards and Quality is responsible for the OPO regulations.

CMS’s Center for Medicare is responsible for Medicare reimbursement and conditions for participation.
Oversight Authority

OPOs, transplant programs, and histocompatibility laboratories must be OPTN members to participate in the organ donation and transplant system. \( ^{xxii} \)

Pursuant to the OPTN Bylaws, \( ^{xxii} \) the OPTN can impose two forms of adverse actions on an OPTN member: probation or designate it as a member not in good standing.

Adverse actions are publicly announced, and if a member is designated as a member not in good standing, it will be subject to a corrective action plan and at least one unannounced on-site review. \( ^{xxx} \) Additionally, members not in good standing cannot vote in OPTN matters, and personnel associated with the member cannot serve on OPTN committees and the Board of Directors. \( ^{xxvi} \)

By regulation, the OPTN cannot unilaterally terminate OPTN membership. The OPTN can only recommend to the Secretary to take action. \( ^{xxvii} \) The Secretary is not compelled to wait for any OPTN recommendation to take action against a member nor is the Secretary required to act on a OPTN recommendation. \( ^{xxviii} \)

Oversight Authority

HRSA is responsible for managing and overseeing the OPTN and SRTR contractors. HRSA and the Final Rule require the OPTN to monitor and review OPTN member performance. \( ^{xxix} \)

Any individual or entity may submit written critical comments related to the way the OPTN is carrying out its duties or Secretarial policies related to the OPTN. \( ^{xxix} \) The Secretary may reject the comments, direct the OPTN to revise policies or practices consistent with the Secretary's direction, or take other action deemed appropriate by the Secretary. \( ^{xxix} \)

Transplant Programs

CMS can suspend Medicare payments to a hospital’s transplant program if CMS finds the program is not in compliance with the Medicare conditions of participation for transplant programs. \( ^{xxxviii} \) Of note, a condition of participation in the Medicare program for transplant programs is membership in the OPTN. \( ^{xxxv} \)

Histocompatibility Laboratories

CMS can revoke a histocompatibility laboratory’s CLIA certificate, \( ^{xli} \) or suspend its ability to receive Medicare payments, \( ^{xlii} \) if it does not comply with the specific requirements required of such laboratories that conduct testing for transplants, or any other condition of participation applicable to all laboratories. \( ^{xlii} \)

As of the date of termination of Medicare approval, Medicare will not pay for a transplant program or a histocompatibility laboratory’s services.
### Monitoring Member Performance
The OPTN is required by regulation to conduct ongoing and periodic peer reviews and evaluations of each OPO and transplant program. The OPTN focuses on OPO and transplant program quality improvement.

The OPTN establishes performance metrics for OPOs and transplant hospitals to conduct ongoing and periodic reviews and evaluations of each member OPO and transplant hospital for compliance with membership rules, requirements to be a designated transplant program, and OPTN policies.

### CMS' OPO Final Rule
CMS' OPO Final Rule implemented new donation rate and transplant rate measures. CMS reviews OPO performance every 12 months during the 4-year recertification cycle. CMS assigns each OPO to a tier at the end of each recertification cycle. OPOs that are ranked in the top 25 percentile will be assigned to Tier 1 and recertified for another 4 years. Tier 2 OPOs are those whose performance on both measures exceeds the median but are not in the top 25 percentile. Tier 2 OPOs will be required to compete to retain their Donation Service Areas (DSAs). Tier 3 OPOs are those that perform below the median on one or both measures. Tier 3 OPOs will be decertified and will not be able to compete for any other open DSA.

### Monitoring Member Performance
The OPTN contract requires the OPTN contractor to immediately report patient safety events that pose a significant risk to patient health, public safety, or the integrity of the transplant system.

HRSA may direct that the contractor conduct a special review of OPTN members when concerns related to compliance with OPTN obligations and/or risks to patient health or public safety exist.

### Monitoring Member Performance
The OPTN contractor meets at least weekly with HRSA.

In addition to regular meetings with the OPTN contractor, HRSA serves as an ex-officio member of the OPTN Board of Directors, OPTN Executive Committee, OPTN Finance Committee, OPTN Network Operations Oversight Committee, OPTN Nomination Committee, and 22 other OPTN Committees.

The Organ Transplant Affinity Group (OTAG) was established by HRSA and CMS in 2021 to ensure coordination and collaboration related to organ donation and transplant.

### Appendix
- [Current Committees, Organ Procurement & Transplantation Network – Health Resources and Servs. Admin.](https://optn.transplant.hrsa.gov/about/committees/).
- [History & NOTA, Organ Procurement and Transplantation Network](https://optn.transplant.hrsa.gov/about/history-nota/). To address the nation’s critical organ donation shortage and improve the organ matching and placement process, the U.S. Congress passed the [National Organ Transplant Act (NOTA; P.L. 98-507)](https:// ald/). The act established the OPTN to maintain a national registry for organ matching. The act also called for the network to be operated by a private, non-profit organization under federal contract. Following further study and recommendations from a task force commissioned through NOTA, the U.S. Department of Health and Human Services (HHS) solicited proposals in 1986 for the operation of the OPTN. In 2000, The U.S. Department of Health and Human Services (HHS) implemented a final rule establishing a regulatory framework for the structure and operations of the OPTN. HRSA awarded an OPTN contract in 1986, 1987, 1990, 1993, 1996, 2000, 2005, and 2019.
Congress enacted the Securing the U.S. Organ Procurement and Transplantation Network Act (P.L. 118-14) to lift the cap on federal funding for the OPTN. Prior to the legislation being enacted, the cap on appropriations was $7 million each fiscal year.


OPTN Bylaws at p. 211 (Termination of membership requires Secretarial approval.) (July 27, 2023).

OPTN Bylaws at p. 207 (July 27, 2023). Additionally, a member not in good standing must present at least once before the OPTN's Membership and Professional Standards Committee (MPSC) to provide an update on the member's corrective action plan and ongoing compliance with OPTN obligations.

OPTN Bylaws at p. 210-11 (July 27, 2023) (explaining that even if the OPTN Board of Directors finds that a member's violations pose a severe and urgent risk to patient health and safety, the Board can only recommend that the Secretary take immediate action without a required interview or hearing).

42 C.F.R. § 486.312(e); see also 42 U.S.C. § 1320b-8 (b)(1)(A)(ii) ("The Secretary shall provide that payment may be made under title XVIII or XIX with respect to organ procurement costs attributable to payments made to an organ procurement agency only if the agency . . . has been certified or recertified by the Secretary within the previous 2 years (4 years if the Secretary determines appropriate for an organization on the basis of its past practices) as meeting the standards to be a qualified organ procurement organization.").

Id.

42 C.F.R. § 486.320.

42 C.F.R. § 488.61; 42 C.F.R. § 482.72 et. seq.

42 C.F.R. § 482.72.

42 C.F.R. § 493.1806.

42 C.F.R. § 493.1807.

42 C.F.R. § 493.1278(f) (specific requirements for histocompatibility laboratories performing services for transplant); 42 C.F.R. Part 493 (general requirements for laboratories).

42 C.F.R. § 121.10(b)(1) (The OPTN shall design appropriate plans and procedures, including survey instruments, a peer review process, and data systems for purposes of . . . conducting ongoing and periodic reviews and evaluations of each member OPO and transplant hospital for compliance with these rules and OPTN policies") (emphasis added).

OPTN Member Monitoring Process, Organ Procurement and Transplantation Network, at p. 12-13 (Aug. 1, 2023),

https://optn.transplant.hrsa.gov/media/gqrbxjba/optn_member_monitoring_processes.pdf ("The OPTN reviews both OPO and transplant hospital performance. The MPSC’s goal is to work with members identified through these reviews to implement performance improvement measures.").

42 C.F.R. § 121.10(b).

OPTN Member Monitoring Process, Organ Procurement and Transplantation Network, at p. 19 (Aug. 1, 2023),


Organ Transplantation Affinity Group (OTAG): Strengthening Accountability, Equity and Performance, Ctrs. for Medicare & Medicaid Servs (Sept. 15, 2023),